Kemin (Metformin Hydrochloride) is a biguanide type oral anti-hyperglycemic drug used in the management of type II diabetes. It lowers both basal and postprandial plasma glucose. Mechanism of action of metformin is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization. Metformin leads to fall in serum androgens, luteinizing hormone and an improvement in fertility and fibrinolysis in both obese and lean women with PCOS (Polycystic Ovary Syndrome).

Kemin-SR Tablet (Metformin Hydrochloride sustained release tablet) is used in the management of type II diabetes when diet has failed and especially if the patient is overweight. Kemin-SR, as monotherapy, is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type II diabetes.

Metformin HCl can be given alone as initial therapy or can be administered in combination with oral hypoglycemic agent, insulin or glitazones when diet and exercise plus the single agent do not result in adequate glycemic control. It is also indicated in the treatment of PCOS (Polycystic Ovary Syndrome) including chronic anovulation, hirsutism and associated vascular disease in women. May also be given in combination with clomiphene citrate to enhance the ovulatory response and with oral contraceptives to have better results in hirsutism. It is advocated for IGT (Impaired Glucose Tolerance) patients to prevent progression to type II diabetes.